LRP1 facilitates hepatic glycogenesis by improving the insulin signaling pathway in HFD-fed mice

Abstract

Background: LDL receptor-related protein-1 (LRP1) is a cell-surface receptor that functions in diverse physiological pathways. We previously demonstrated that hepatocyte-specific LRP1 deficiency (hLRP1KO) promotes diet-induced insulin resistance and increases hepatic gluconeogenesis in mice. However, it remains unclear whether LRP1 regulates hepatic glycogenesis.

Methods: Insulin signaling, glycogenic gene expression, and glycogen content were assessed in mice and HepG2 cells. The pcDNA 3.1 plasmid and adeno-associated virus serotype 8 vector (AAV8) were used to overexpress the truncated β-chain (βΔ) of LRP1 both in vitro and in vivo.

Results: On a normal chow diet, hLRP1KO mice exhibited impaired insulin signaling and decreased glycogen content. Moreover, LRP1 expression in HepG2 cells was significantly repressed by palmitate in a dose- and time-dependent manner. Both LRP1 knockdown and palmitate treatment led to reduced phosphorylation of Akt and GSK3β, increased levels of phosphorylated glycogen synthase (GYS), and diminished glycogen synthesis in insulin-stimulated HepG2 cells, which was restored by exogenous expression of the βΔ-chain. By contrast, AAV8-mediated hepatic βΔ-chain overexpression significantly improved the insulin signaling pathway, thus activating glycogenesis and enhancing glycogen storage in the livers of high-fat diet (HFD)-fed mice.

Conclusion: Our data revealed that LRP1, especially its β-chain, facilitates hepatic glycogenesis by improving the insulin signaling pathway, suggesting a new therapeutic strategy for hepatic insulin resistance-related diseases.

Keywords

glycogenesis / insulin resistance / insulin signaling pathway / LRP1

References

[1] Driessen S, Francque SM, Anker SD, et al. Metabolic dysfunction associated steatotic liver disease and the heart. Hepatology. 2024.

[2] Jin J, He Y, Guo J, et al. BACH1 controls hepatic insulin signaling and glucose homeostasis in mice. Nat Commun. 2023;14:8428.

[3] Samuel VT, Shulman GI. Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases. Cell Metab. 2018;27:22-41.

[4] Santoleri D, Titchenell PM. Resolving the paradox of hepatic insulin resistance. Cell Mol Gastroenterol Hepatol. 2019;7:447-456.

[5] Petersen MC, Vatner DF, Shulman GI. Regulation of hepatic glucose metabolism in health and disease. Nat Rev Endocrinol. 2017;13:572-587.

[6] Su Z, Nie Y, Huang X, et al. Mitophagy in hepatic insulin resistance: therapeutic potential and concerns. Front Pharmacol. 2019;10:1193.

[7] Shearer AM, Wang Y, Fletcher EK, et al. PAR2 promotes impaired glucose uptake and insulin resistance in NAFLD through GLUT2 and Akt interference. Hepatology. 2022;76:1778-1793.

[8] Samuel VT, Shulman GI. The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J Clin Invest. 2016;126:12-22.

[9] Mineo C. Lipoprotein receptor signalling in atherosclerosis. Cardiovasc Res. 2020;116:1254-1274.

[10] Lin LL, Kost ER, Lin CL, et al. PAI-1-dependent inactivation of SMAD4-modulated junction and adhesion complex in obese endometrial cancer. Cell Rep. 2020;33:108253.

[11] Sizova O, John LS, Ma Q, Molldrem JJ. Multi-faceted role of LRP1 in the immune system. Front Immunol. 2023;14:1166189.

[12] Terrand J, Bruban V, Zhou L, et al. LRP1 controls intracellular cholesterol storage and fatty acid synthesis through modulation of Wnt signaling. J Biol Chem. 2009;284:381-388.

[13] Hamlin AN, Basford JE, Jaeschke A, Hui DY. LRP1 protein deficiency exacerbates palmitate-induced steatosis and toxicity in hepatocytes. J Biol Chem. 2016;291:16610-16619.

[14] Smith CE, Tucker KL, Lee YC, Lai CQ, Parnell LD, Ordovas JM. Low-density lipoprotein receptor-related protein 1 variant interacts with saturated fatty acids in Puerto Ricans. Obesity (Silver Spring). 2013;21:602-608.

[15] Delgado-Lista J, Perez-Martinez P, Solivera J, et al. Top single nucleotide polymorphisms affecting carbohydrate metabolism in metabolic syndrome: from the LIPGENE study. J Clin Endocrinol Metab. 2014;99:E384-E389.

[16] Ding Y, Xian X, Holland WL, Tsai S, Herz J. Low-density lipoprotein receptor-related protein-1 protects against hepatic insulin resistance and hepatic steatosis. EBioMedicine. 2016;7:135-145.

[17] Xian X, Ding Y, Dieckmann M, et al. LRP1 integrates murine macrophage cholesterol homeostasis and inflammatory responses in atherosclerosis. elife. 2017;6:e29292.

[18] Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005;307:1098-1101.

[19] Rong Guo X, Li Wang X, Chen Y, et al. ANGPTL8/betatrophin alleviates insulin resistance via the Akt-GSK3beta or Akt-FoxO1 pathway in HepG2 cells. Exp Cell Res. 2016;345:158-167.

[20] Zurhove K, Nakajima C, Herz J, Bock HH, May P. Gamma-secretase limits the inflammatory response through the processing of LRP1. Sci Signal. 2008;1:ra15.

[21] Mao H, Lockyer P, Li L, et al. Endothelial LRP1 regulates metabolic responses by acting as a co-activator of PPARgamma. Nat Commun. 2017;8:14960.

[22] Norton L, Shannon C, Gastaldelli A, DeFronzo RA. Insulin: the master regulator of glucose metabolism. Metabolism. 2022;129:155142.

[23] Henderson GC. Plasma free fatty acid concentration as a modifiable risk factor for metabolic disease. Nutrients. 2021;13:2590.

[24] White MF, Kahn CR. Insulin action at a molecular level -100 years of progress. Mol Metab. 2021;52:101304.

[25] Lewis GF, Carpentier AC, Pereira S, Hahn M, Giacca A. Direct and indirect control of hepatic glucose production by insulin. Cell Metab. 2021;33:709-720.

[26] Hatting M, Tavares CDJ, Sharabi K, Rines AK, Puigserver P. Insulin regulation of gluconeogenesis. Ann N Y Acad Sci. 2018;1411:21-35.

[27] Uehara K, Lee WD, Stefkovich M, et al. mTORC1 controls murine postprandial hepatic glycogen synthesis via Ppp1r3b. J Clin Invest. 2024;e173782.

[28] Jiang S, Young JL, Wang K, Qian Y, Cai L. Diabetic-induced alterations in hepatic glucose and lipid metabolism: the role of type 1 and type 2 diabetes mellitus (review). Mol Med Rep. 2020;22:603-611.

[29] Lee J, Kim MS. The role of GSK3 in glucose homeostasis and the development of insulin resistance. Diabetes Res Clin Pract. 2007;77(suppl 1):S49-S57.

[30] Actis Dato V, Chiabrando GA. The role of low-density lipoprotein receptor-related protein 1 in lipid metabolism, glucose homeostasis and inflammation. Int J Mol Sci. 2018;19:1780.

[31] Wu YS, Li ZM, Chen YT, et al. Berberine improves inflammatory responses of diabetes mellitus in Zucker diabetic fatty rats and insulin-resistant HepG2 cells through the PPM1B pathway. J Immunol Res. 2020;2020:2141508.

[32] Rotman Y, Neuschwander-Tetri BA. Liver fat accumulation as a barometer of insulin responsiveness again points to adipose tissue as the culprit. Hepatology. 2017;65:1088-1090.

[33] Auderset L, Landowski LM, Foa L, Young KM. Low density lipoprotein receptor related proteins as regulators of neural stem and progenitor cell function. Stem Cells Int. 2016;2016:2108495.

[34] Robinson KA, Sens DA, Buse MG. Pre-exposure to glucosamine induces insulin resistance of glucose transport and glycogen synthesis in isolated rat skeletal muscles. Study of mechanisms in muscle and in rat-1 fibroblasts overexpressing the human insulin receptor. Diabetes. 1993;42:1333-1346.

[35] Crook ED, McClain DA. Regulation of glycogen synthase and protein phosphatase-1 by hexosamines. Diabetes. 1996;45:322-327.

[36] Parker GJ, Lund KC, Taylor RP, McClain DA. Insulin resistance of glycogen synthase mediated by o-linked N-acetylglucosamine. J Biol Chem. 2003;278:10022-10027.

[37] Soesanto YA, Luo B, Jones D, et al. Regulation of Akt signaling by O-GlcNAc in euglycemia. Am J Physiol Endocrinol Metab. 2008;295:E974-E980.

[38] Singh LP, Gennerette D, Simmons S, Crook ED. Glucose-induced insulin resistance of phosphatidylinositol 3′-OH kinase and AKT/PKB is mediated by the hexosamine biosynthesis pathway. J Diabetes Complicat. 2001;15:88-96.

RIGHTS & PERMISSIONS

2024 The Authors. Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.